vs
Side-by-side financial comparison of Ispire Technology Inc. (ISPR) and Xtant Medical Holdings, Inc. (XTNT). Click either name above to swap in a different company.
Xtant Medical Holdings, Inc. is the larger business by last-quarter revenue ($32.4M vs $20.3M, roughly 1.6× Ispire Technology Inc.). Xtant Medical Holdings, Inc. runs the higher net margin — 0.2% vs -32.5%, a 32.7% gap on every dollar of revenue. On growth, Xtant Medical Holdings, Inc. posted the faster year-over-year revenue change (2.7% vs -51.5%). Xtant Medical Holdings, Inc. produced more free cash flow last quarter ($5.0M vs $-4.0M). Over the past eight quarters, Xtant Medical Holdings, Inc.'s revenue compounded faster (7.7% CAGR vs -17.8%).
Ispire Technology Inc. is a global tech firm specializing in R&D, manufacturing and sales of advanced vaporization hardware and supporting consumables. It serves nicotine and legal cannabis consumer markets, operates two core segments of hardware and branded cannabis products, covers North America, Europe and Asia-Pacific, delivering compliant innovative vapor solutions for B2B partners and end users.
Xtant Medical Holdings, Inc. is a global medical technology company that develops, manufactures and markets orthobiologic products, neurosurgery devices, and regenerative medicine solutions for orthopedic and neurological care providers. It serves patients and medical institutions across North America, Europe and the Asia-Pacific, with core segments covering spinal surgery supplies and bone regeneration products.
ISPR vs XTNT — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.3M | $32.4M |
| Net Profit | $-6.6M | $57.0K |
| Gross Margin | 17.1% | 54.9% |
| Operating Margin | -33.9% | -2.9% |
| Net Margin | -32.5% | 0.2% |
| Revenue YoY | -51.5% | 2.7% |
| Net Profit YoY | 17.4% | 101.8% |
| EPS (diluted) | $-0.12 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.3M | $32.4M | ||
| Q3 25 | $30.4M | $33.3M | ||
| Q2 25 | $20.1M | $35.4M | ||
| Q1 25 | $26.2M | $32.9M | ||
| Q4 24 | $41.8M | $31.5M | ||
| Q3 24 | $39.3M | $27.9M | ||
| Q2 24 | $37.3M | $29.9M | ||
| Q1 24 | $30.0M | $27.9M |
| Q4 25 | $-6.6M | $57.0K | ||
| Q3 25 | $-3.3M | $1.3M | ||
| Q2 25 | $-14.8M | $3.5M | ||
| Q1 25 | $-10.9M | $58.0K | ||
| Q4 24 | $-8.0M | $-3.2M | ||
| Q3 24 | $-5.6M | $-5.0M | ||
| Q2 24 | $-3.5M | $-3.9M | ||
| Q1 24 | $-5.9M | $-4.4M |
| Q4 25 | 17.1% | 54.9% | ||
| Q3 25 | 17.0% | 66.1% | ||
| Q2 25 | 12.3% | 68.6% | ||
| Q1 25 | 18.2% | 61.5% | ||
| Q4 24 | 18.5% | 50.9% | ||
| Q3 24 | 19.5% | 58.4% | ||
| Q2 24 | 28.3% | 62.1% | ||
| Q1 24 | 20.4% | 62.1% |
| Q4 25 | -33.9% | -2.9% | ||
| Q3 25 | -8.9% | 7.6% | ||
| Q2 25 | -72.7% | 13.1% | ||
| Q1 25 | -40.4% | 3.2% | ||
| Q4 24 | -17.6% | -6.0% | ||
| Q3 24 | -13.4% | -13.5% | ||
| Q2 24 | -9.2% | -9.8% | ||
| Q1 24 | -18.8% | -12.4% |
| Q4 25 | -32.5% | 0.2% | ||
| Q3 25 | -10.7% | 3.9% | ||
| Q2 25 | -73.4% | 10.0% | ||
| Q1 25 | -41.5% | 0.2% | ||
| Q4 24 | -19.1% | -10.0% | ||
| Q3 24 | -14.2% | -18.0% | ||
| Q2 24 | -9.4% | -12.9% | ||
| Q1 24 | -19.7% | -15.8% |
| Q4 25 | $-0.12 | $0.00 | ||
| Q3 25 | $-0.06 | $0.01 | ||
| Q2 25 | $-0.26 | $0.02 | ||
| Q1 25 | $-0.19 | $0.00 | ||
| Q4 24 | $-0.14 | $-0.02 | ||
| Q3 24 | $-0.10 | $-0.04 | ||
| Q2 24 | $-0.07 | $-0.03 | ||
| Q1 24 | $-0.11 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $17.6M | $17.1M |
| Total DebtLower is stronger | — | $11.0M |
| Stockholders' EquityBook value | $-7.7M | $51.0M |
| Total Assets | $84.4M | $94.1M |
| Debt / EquityLower = less leverage | — | 0.22× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.6M | $17.1M | ||
| Q3 25 | $22.7M | $10.4M | ||
| Q2 25 | $24.4M | $6.9M | ||
| Q1 25 | $23.5M | $5.0M | ||
| Q4 24 | $34.4M | $6.2M | ||
| Q3 24 | $37.7M | $6.6M | ||
| Q2 24 | $35.1M | $5.4M | ||
| Q1 24 | $39.5M | $4.5M |
| Q4 25 | — | $11.0M | ||
| Q3 25 | — | $17.4M | ||
| Q2 25 | — | $22.3M | ||
| Q1 25 | — | $22.2M | ||
| Q4 24 | — | $22.0M | ||
| Q3 24 | — | $19.1M | ||
| Q2 24 | — | $21.8M | ||
| Q1 24 | — | $16.8M |
| Q4 25 | $-7.7M | $51.0M | ||
| Q3 25 | $-1.8M | $50.4M | ||
| Q2 25 | $604.7K | $48.5M | ||
| Q1 25 | $14.8M | $43.9M | ||
| Q4 24 | $24.2M | $43.0M | ||
| Q3 24 | $30.7M | $45.7M | ||
| Q2 24 | $34.5M | $45.0M | ||
| Q1 24 | $35.9M | $47.7M |
| Q4 25 | $84.4M | $94.1M | ||
| Q3 25 | $96.4M | $106.3M | ||
| Q2 25 | $102.2M | $103.5M | ||
| Q1 25 | $115.7M | $95.8M | ||
| Q4 24 | $132.0M | $93.8M | ||
| Q3 24 | $129.0M | $98.9M | ||
| Q2 24 | $122.6M | $95.6M | ||
| Q1 24 | $108.0M | $93.9M |
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.46× | ||
| Q1 25 | — | 0.51× | ||
| Q4 24 | — | 0.51× | ||
| Q3 24 | — | 0.42× | ||
| Q2 24 | — | 0.48× | ||
| Q1 24 | — | 0.35× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.0M | $5.4M |
| Free Cash FlowOCF − Capex | $-4.0M | $5.0M |
| FCF MarginFCF / Revenue | -19.9% | 15.4% |
| Capex IntensityCapex / Revenue | 0.3% | 1.2% |
| Cash ConversionOCF / Net Profit | — | 94.39× |
| TTM Free Cash FlowTrailing 4 quarters | $-14.2M | $10.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.0M | $5.4M | ||
| Q3 25 | $-1.2M | $4.6M | ||
| Q2 25 | $4.7M | $1.3M | ||
| Q1 25 | $-12.5M | $1.3M | ||
| Q4 24 | $-3.2M | $665.0K | ||
| Q3 24 | $3.6M | $-1.7M | ||
| Q2 24 | $-1.4M | $-5.1M | ||
| Q1 24 | $3.4M | $-5.8M |
| Q4 25 | $-4.0M | $5.0M | ||
| Q3 25 | $-1.2M | $4.2M | ||
| Q2 25 | $3.7M | $910.0K | ||
| Q1 25 | $-12.7M | $87.0K | ||
| Q4 24 | $-3.2M | $-7.0K | ||
| Q3 24 | $3.3M | $-3.8M | ||
| Q2 24 | $-2.2M | $-5.7M | ||
| Q1 24 | $3.3M | $-6.5M |
| Q4 25 | -19.9% | 15.4% | ||
| Q3 25 | -3.9% | 12.6% | ||
| Q2 25 | 18.6% | 2.6% | ||
| Q1 25 | -48.4% | 0.3% | ||
| Q4 24 | -7.7% | -0.0% | ||
| Q3 24 | 8.5% | -13.7% | ||
| Q2 24 | -5.9% | -18.9% | ||
| Q1 24 | 10.9% | -23.4% |
| Q4 25 | 0.3% | 1.2% | ||
| Q3 25 | 0.0% | 1.3% | ||
| Q2 25 | 4.8% | 1.0% | ||
| Q1 25 | 0.7% | 3.6% | ||
| Q4 24 | 0.1% | 2.1% | ||
| Q3 24 | 0.7% | 7.5% | ||
| Q2 24 | 2.0% | 1.9% | ||
| Q1 24 | 0.3% | 2.8% |
| Q4 25 | — | 94.39× | ||
| Q3 25 | — | 3.53× | ||
| Q2 25 | — | 0.36× | ||
| Q1 25 | — | 22.03× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ISPR
Segment breakdown not available.
XTNT
| Orthobiologics | $18.3M | 57% |
| Spinal Implant | $9.4M | 29% |
| License Revenue | $4.6M | 14% |
